Introduction {#Sec1}
============

Carborane (C~2~B~10~H~12~, Fig. [1](#Fig1){ref-type="fig"}) is a spherical compound formed by one or more boron peaks of polyhedral boron compounds, which is formed by carbon atoms. The volume is similar to that of a benzene ring \[[@CR1]--[@CR5]\]. This is a special large steric skeleton with a very strong hydrophobic structure. Therefore, improvement of the chemical structure can alter the stability, water solubility, and biological activity of compatibility and allow wider applications of carborane as a BNCT agent \[[@CR6]--[@CR9]\]. Boron neutron capture therapy (BNCT) was first proposed as a potential cancer therapy in 1936, based on the thermal neutron captured by ^10^B atoms then produces a ^4^He (α-particle) and a ^7^Li ion \[[@CR10], [@CR11]\]. However, its successful application in the treatment of cancer patients still presents a challenge in medical research \[[@CR12]\]. A major challenge in designing boron containing drugs for BNCT of cancer is the selective delivery of ^10^B to the tumor as well as water solubility \[[@CR13]\]. Our synthetic strategy was to use heterocyclic alkyl chains as a boron delivery system, the target molecules being the heterocyclic alkyl oxime chains in which the boron functionality was present as a *ortho*-carborane. The large number of boron atoms has a clear advantage for BNCT \[[@CR14]\]. This paper reports the hydrophilic carboranylbenzyloxime moiety, such as alkylmorpholine, alkylpiperidine, phenoxyalkyl, and pyridine, on carbon--oxygen combined with chemical bonding. These compounds have higher solubility in polar solvents and increased the boron uptake in tumor cells, highlighting the potential use of carborane as a hydrophilic carrier into the body that can pass the Blood Brain Barrier (BBB rule) to the cells within the organization for drug evaluation.Fig. 1Comparison of the *o*-Carborane and benzene

Experimental {#Sec2}
============

All manipulations were performed under a dry nitrogen atmosphere using standard Schlenk techniques. Tetrahydrofuran (THF) was purchased from Aladdin Pure Chemical Company and dried over sodium metal distillation prior use. The reactions were monitored on Merck F-254 pre-coated TLC plastic sheets using hexane as the mobile phase. All yields refer to the isolated yields of the products after column chromatography using silica gel (200--230 mesh). All glassware, syringes, magnetic stirring bars, and needles were dried overnight in a convection oven. *Ortho*-carborane (C~2~H~2~B~10~H~10~) was purchased from HENAN WANXIANG Fine Chemical Company and used after sublimation. The NMR spectra were recorded on a Bruker 300 spectrometer operated and the chemical shifts were measured relative to the internal residual peaks from the lock solvent (99.9% CDCl~3~ and CD~3~COCD~3~), and then referenced to Si(CH~3~)~4~ (0.00 ppm). The Fourier transform infrared (FTIR) spectra of the samples were recorded on an Agilent Cary 600 Series FT-IR spectrometer using KBr disks. Elemental analyses were performed using a Carlo Erba Instruments CHNS--O EA1108 analyzer (Additional file [1](#MOESM1){ref-type="media"}).

Synthetic routes and experimental data {#Sec3}
--------------------------------------

Synthesis of bis(3-methoxybenzyl)-*ortho*-carborane (**1**). A 2.5 M *n*-BuLi (4.0 mL, 10 mmol) solution was added via a syringe to a solution of *o*-carborane (1.44 g, 10 mmol) in 50 mL of THF at − 78 °C. A solution of 1-(bromomethyl)-3-methoxybenzene (4.22 g, 21 mmol) in THF 10 mL was added slowly to the reaction flask at − 78 °C, and the reaction temperature was maintained at − 78 °C for 1 h. The reaction mixture was then warmed slowly to room temperature, stirred for an additional 12 h, and quenched with distilled H~2~O (30 mL). The crude product was then extracted with methylene chloride (30 mL × 3). The organic layer was washed with H~2~O, dried with anhydrous Na~2~SO~4~, and filtered then concentrated. The residue was purified by flash column chromatography (ethyl acetate/hexane 1:10) to give compound **1** as a colorless oil: yield: 3.6 g (93%). IR(KBr pellet), cm^−1^, ν: (B-H~*o*-carborane~) 2593. ^1^HNMR (CDCl~3~), δ, ppm: 3.2--0.8 (br, B-H~*o*-carborane~, 10H), 3.61 (s, --CH~2~, 4H), 3.83 (s, --OCH~3~, 6H), 6.77 (s, 1-H~benzene~, 2H), 6.84--6.82 (d, *J* = 6.9 Hz, 2-H~benzene~, 2H), 6.90--6.88 (d, *J* = 6.9 Hz, 3-H~benzene~, 2H), 7.32--7.29 (m, 4-H~benzene~, 2H). Found, %: C 56.31; H 7.65. C~18~H~28~B~10~O~2~. Calculated, %: C 56.23; H 7.34.

Synthesis of 1,1′-(4-caboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one) (**2**). Acetyl chloride (1.4 mL, 20 mmol) was added via a syringe to a solution of aluminum chloride (2.6 g, 20 mmol) in 50 mL of methylene chloride at 0 °C and stirred for 30 min. A solution of compound **1** (3.5 g, 10 mmol) in methylene chloride 10 mL was added slowly to the reaction flask at 0 °C, and the reaction temperature was maintained at 0 °C for 30 min. The reaction mixture was then warmed slowly to room temperature, stirred for an additional 3 h, and quenched with a saturated NaHCO~3~ (30 mL) solution. The crude product was then extracted, and the organic layer was washed with H~2~O, dried with anhydrous Na~2~SO~4~, and filtered then concentrated. The residue was purified by flash column chromatography (ethyl acetate/hexane 1:8) to give compound **2** as a colorless oil: yield: 4.1 g (97%). IR (KBr pellet), cm^−1^, ν: (B-H~*o*-carborane~) 2602. ^1^HNMR(CDCl~3~), δ, ppm: 3.2--0.8 (br, B-H~*o*-carborane~, 10H), 3.64 (s, --CH~3~, 6H), 3.66 (s, --CH~2~, 4H), 3.95 (s, --OCH~3~, 6H), 6.82 (s, 1-H~benzene~, 2H), 6.89--6.86 (d, *J* = 7.8 Hz, 2-H~benzene~, 2H), 7.77--7.74 (d, *J *= 7.8 Hz, 3-H~benzene~, 2H). Found, %: C 56.42; H 6.67. C~22~H~32~B~10~O~4~. Calculated, %: C 56.39; H 6.88.

Synthesis of (*Z*,*Z*′)-1,1′-(4-caboranyldimethyl)-bis(2-methoxyphenylethan-1-oxime) (**3**). A solution of compound **2** (3.8 g, 8.1 mmol) and hydroxylamine (1.2 g, 17.8 mmol) in 40 mL of methanol was heated under reflux for 2 h. The reaction mixture was then cooled to room temperature, and the crude product was concentrated. The residue was purified by flash column chromatography (ethyl acetate/hexane 1:4) to give compound **3** as a colorless oil: Yield: 3.7 g (92%). IR (KBr pellet), cm^−1^, ν: (B-H~*o*-carborane~) 2586. ^1^H NMR (CD~3~COCD~3~), δ, ppm: 3.16 (s, --CH~3~, 6H), 3.2--0.8 (br, B-H~*o*-carborane~, 10H), 3.88 (s, --OCH~3~, 6H), 3.93 (s, --CH~2~, 4H), 6.97--6.95 (d, *J *= 7.5 Hz, 2-H~benzene~, 2H), 7.05 (s, 1-H~benzene~, 2H), 7.30--7.28 (d, *J* = 7.5 Hz, 3-H~benzene~, 2H). Found, %: C 52.68; H 6.81; N 5.69. C~22~H~34~B~10~N~2~O~4~. Calculated, %: C 52.99; H 6.87; N 5.62.

Synthesis of (1*Z,*1′*Z*)-1,1′-(carboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one)-*O,O*-dipyridin-2-ylmethyldioxime (**4**). A solution of compound **3** (0.7 g, 1.4 mmol) and potassium carbonate (0.4 g, 3.0 mmol) in 10 mL of acetonitrile was stirred at room temperature for 30 min. Subsequently, (2-bromomethyl)pyridine (0.5 g, 3.0 mmol) was added at room temperature, and then heated under reflux for 5 h. The crude product was then concentrated, and the residue was purified by flash column chromatography (ethyl acetate/hexane 1:4) to give compound **4** as a yellow oil: Yield: 0.8 g (88%). IR (KBr pellet), cm^−1^, ν: (B-H~*o*-carborane~) 2607. ^1^HNMR (CD~3~Cl), δ, ppm: 2.31 (s, --CH~2~, 6H), 3.2--0.8 (br, B-H~*o*-carborane~, 10H), 3.63 (s, --CH~3~, 4H), 3.84 (s, --OCH~3~, 6H), 5.37 (s, --CH~2~, 2H), 6.73 (s, 1-H~benzene~, 2H), 6.80--6.77 (d, *J *= 7.8 Hz, 2-H~benzene~, 2H), 7.29--7.24 (m, 3-H~benzene\ and\ pyridine~, 4H), 7.47--7.44 (d, *J *= 7.8 Hz, 3-H~pyridine~, 2H), 7.76--7.70 (t, *J *= 7.8 Hz, 2-H~pyridine~, 2H), 8.61--8.59 (d, *J *= 4.8 Hz, 1-H~pyridine~, 2H). Found, %: C 59.36; H 6.63; N 8.35. C~34~H~44~B~10~N~4~O~4~. Calculated, %: C 59.98; H 6.51; N 8.23.

Synthesis of (1*Z,*1′*Z*)-1,1′-(carboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one)-*O,O*-di(2-phenoxyethyl)dioxime (**5**). A procedure analogous to the preparation of **4** was used and a colorless oil was obtained. Yield: 0.9 g (89%). IR (KBr pellet), cm^−1^, ν: (B-H~*o*-carborane~) 2577. ^1^H NMR (CD~3~Cl) δ, ppm: 2.22 (s, --CH~3~, 6H), 3.2--0.8 (br, B-H~*o*-carborane~, 10H), 3.64 (s, --CH~2~, 4H), 3.85 (s, --OCH~3~, 6H), 4.31--4.28 (t, *J *= 4.8 Hz, --CH~2\ alkyl-1~, 4H), 4.56--4.52 (t, *J *= 5.1 Hz, --CH~2\ alkyl-2~ 4H), 6.75 (s, 1-H~benzene-1~ 2H), 6.83--6.80 (d, *J *= 7.5 Hz, 2-H~benzene-1~, 2H), 7.00--6.95 (m, 1-H~benzene-2~, 6H), 7.34--7.29 (m, 2-H~benzene-1\ and\ 2~, 6H). Found, %: C 61.47; H 6.92; N 3.84. C~38~H~50~B~10~N~2~O~6~. Calculated, %: C 61.77; H 6.82; N 3.79.

Synthesis of (1*Z,*1′*Z*)-1,1′-(carboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one)-*O,O*-di(3-phenoxypropyl)dioxime (**6**). A procedure analogous to the preparation of **4** was used and a colorless oil was obtained. Yield: 0.9 g (86%). IR (KBr pellet), cm^−1^, ν: (B--H) 2589. ^1^H NMR(CD~3~Cl), δ, ppm: 2.25--2.17 (m, --CH~3~ and -CH~2\ alkyl-1~, 10H), 3.2--0.8 (br, B-H~*o*-carborane~, 10H), 3.64 (s, --CH~2~, 4H), 3.85 (s, --OCH~3~, 6H), 4.16--4.12 (t, *J *= 6.0 Hz, --CH~2\ alkyl-2~, 4H), 4.40--4.36 (t, *J *= 6.0 Hz, --CH~2\ alkyl-3~, 4H), 6.74 (s, 1-H~benzene-1~, 2H), 6.82--6.79 (d, *J *= 7.8 Hz, 2-H~benzene-1~, 2H), 6.96--6.93 (m, 1-H~benzene-2~, 6H), 7.33--7.30 (m, 2-H~benzene-1\ and\ 2~, 6H). Found, %: C 62.52; H 7.12; N 3.77. C~40~H~54~B~10~N~2~O~6~. Calculated, %: C 62.64; H 7.10; N 3.65.

Synthesis of (1*Z,*1′*Z*)-1,1′-(carboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one)-*O,O*-di(2-piperidin-1-ylethyl)dioxime (**7**). A procedure analogous to the preparation of **4** was used and a colorless oil was obtained. Yield: 0.8 g (82%) colorless oil. IR (KBr pellet), cm^−1^, ν: (B-H~*o*-carborane~) 2591. ^1^H NMR (CD~3~Cl), δ, ppm: 1.47--1.45 (m, 1-H~piperidine~, 4H), 1.64--1.60 (m, 2-H~piperidine~, 4H), 1.88--1.86 (m, 3-H~piperidine~, 4H), 2.19 (s, --CH~3~, 6H), 2.53--2.51 (m, 8H), 2.76--2.72 (t, *J *= 6.0 Hz, --CH~2\ alkyl-1~, 4H), 3.2--0.8 (br, B-H~*o*-carborane~, 10H), 3.63 (s, --CH~2~, 4H), 3.85 (s, --OCH~3~, 6H), 4.36--4.32 (t, *J *= 6.0 Hz, --CH~2\ alkyl-2~, 4H), 6.74 (s, 1-H~benzene~, 2H), 6.82--6.79 (d, *J *= 7.8 Hz, 2-H~benzene~, 2H), 7.31--7.29 (d, *J *= 7.8 Hz, 3-H~benzene~, 2H). Found, %: C 59.65; H 8.34; N 7.68. C~36~H~60~B~10~N~4~O~4~. C 59.97; H 8.39; N 7.77.

Synthesis of (1*Z,*1′*Z)*-1,1′-(carboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one)-*O,O*-di(2-morpholinoethyl)dioxime (**8**). A procedure analogous to the preparation of **4** was used and a colorless oil was obtained. Yield: 0.9 g (84%). IR (KBr pellet), cm^−1^, ν: (B-H~*o*-carborane~) 2596. ^1^HNMR (CD~3~Cl), δ, ppm: 2.52 (s, --CH~3~, 6H), 2.55--2.54 (m, --CH~2\ alkyl-1~, 4H), 2.77--2.72 (t, *J *= 6.9 Hz, --CH~2\ alkyl-2~, 4H), 3.2--0.8 (br, B-H~*o*-carborane~, 10H), 3.64--3.59 (m, 1-H~morpholine~, 8H), 3.76--3.73 (m, 2-H~morpholine~, 8H), 3.85 (s, --OCH~3~, 6H), 6.83--6.76 (m, 2-H~benzene~, 4H), 7.31 (s, 2-H~benzene~, 2H). Found, %: C 56.38; H 7.83; N 7.64. C~34~H~56~B~10~N~4~O~6~. C 56.33; H 7.79; N 7.73.

Cell viability assay (MTT assay) {#Sec4}
--------------------------------

HeLa cells in a 3 × 10^4^/mL cell suspension per hole in 96 well plates were digested by adding 100 μL of a cell suspension and culturing for 24 h to absorb the original culture medium followed by the addition of 200 μL configured compounds-**4**, **5**, **6**, **7**, **8** and BPA ([l]{.smallcaps}-boronphenylalanine). Each concentration was made from 4 compound holes, and the holes around the 96 well plates were sealed with PBS, the negative control. The blank control group lacked the compounds. After 24 h, 20 μL of a MTT solution was added to each hole, and cultured for 4 h. Subsequently, DMSO 150 μL was added to the medium through a suction hole and shaken for 10 min. The OD of each hole was determined at 490 nM, and the sample inhibition rate in different concentrations was calculated: inhibition rate = (Control OD value/Delivery OD value)/Control OD value × 100%. Finally, the IC~50~ value of the sample was calculated using the related software.

Boron uptake {#Sec5}
------------

HeLa cells (5 × 10^3^) were incubated for 48 h in the presence of various concentrations of compounds **4**, **5**, **6**, **7**, **8**, and BPA. After washing three times, the cumulative boron concentration was determined by inductively coupled plasma atomic emission spectrometry (ICP-AES) \[[@CR15], [@CR16]\]. (± is the average value).

Results and discussion {#Sec6}
======================

This paper reports the hydrophilic function of the *ortho*-carboranylbenzyloxime moiety, such as alkylmorpholine, alkylpiperidine, phenoxyalkyl and pyridine, on carbon--oxygen combined with chemical bonding. These compounds have higher solubility in polar solvents and increasing boron uptake in tumor cells within the organization for a drug evaluation.

A general procedure for the preparation for 4-*ortho*-caboranyldimethyl-bis(phenyloxime) consisted of a serial reaction, such as Grignard, Friedel--Crafts, amination, and electrophilic substitution under basic conditions. A series of carborane intermediates 1--3 were prepared using the optimized procedure from the starting material. *Ortho*-Carborane was dissolved in dry tetrahydrofuran at − 78 °C, and treated with a Grignard reagent carbanion, and then substituted with an aromatic halide. Subsequently, aluminum chloride was used in the Friedel--Craft reaction to afford 1,1′-(4-*ortho*-caboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one), which was followed by the addition of hydroxylamine-hydrochloride salt to give the (Z,Z′)-1,1′-(4-*ortho*-Caboranyldimethyl)-bis(2-methoxyphenylethan-1-oxime) form in the presence of compound-**3** (Scheme [1](#Sch1){ref-type="fig"}) \[[@CR17]--[@CR21]\].Scheme 1Preparation of (*Z,Z'*)-1, 1*′*-(4-Caboranyldimethyl)-bis(2-methoxyphenylethan-1-oxime)

Finally, *ortho*-carboranyl hydrophilic ether compounds were generated from (*Z,Z*′)-1,1′-(4-*ortho*-Caboranyldimethyl)-bis(2-methoxyphenylethan-1-oxime) and side hydrophilic alkyl or aromatic halide reagents, followed by a treatment with potassium carbonate to result in the target compounds **4**--**8** (Scheme [2](#Sch2){ref-type="fig"}) \[[@CR22], [@CR23]\]. A treatment of *ortho*-carborane (C~2~H~2~B~10~H~10~) with aromatic halide as a base in tetrahydrofuran produced the target compounds **1**--**3** in moderate yields (1 93, 2 97, and 3 92%). Compounds **1**--**3** showed absorption bands in the infrared (IR) spectrum at 2602 and 2593 cm^−1^. The diagnostic signals of compounds **1**--**3** were the aromatic peaks observed at δ 7.77 and 6.77 in the ^1^H NMR spectra and a broad signal caused by B--H peaks for the *ortho*-carborane units from δ 3.2--0.8.Scheme 2Preparation of (*Z,Z*′)-1,1*′*-(4-Caboranyldimethyl)-bis (hydrophilic functional) derivatives(**4**--**8**)

The major requirement of a BNCT agent is a high water solubility, high boron uptake, and low cytotoxicity. The HeLa cervical carcinoma cells were treated with the candidate compounds **4**--**8** for 2 days, and the cell viability was determined by a MTT assay. Compounds **4**--**8** exhibited boron uptake in the range of 0.106--0.520 ppm (Table [1](#Tab1){ref-type="table"}), and the cell cytotoxicity was in the range of 1.134--2.516 µM, as shown Fig. [2](#Fig2){ref-type="fig"}. In particular, compounds **7** and **8** showed high boron uptake in HeLa cells, and both compounds had higher cytotoxicity than BPA ([l]{.smallcaps}-boronphenylalanine). Morpholine and piperidine is a heterocyclic nitrogen and oxygen member six-ring reagent with a simple structure that improves the water solubility and bioactivity improvement. They are used in the preparation of pharmaceutical drugs for their anti-inflammation, anticancer, and antiviral activity \[[@CR24]--[@CR28]\].Table 1Cytotoxicity (IC~50~) to HeLa cervical carcinoma cellsCompoundsCytotoxicity IC~50~ (μM)^a^Boron uptake (ppm)**4**2.516 ± 0.0220.127 ± 0.113**5**1.924 ± 0.0140.106 ± 0.120**6**2.383 ± 0.3010.114 ± 0.015**7**1.582 ± 0.0270.481 ± 0.026**8**1.134 ± 0.0350.520 ± 0.017BPA4.16 ± 0.0210.226 ± 0.016^a^The results represent the means ± s.d. Fig. 2Accumulation of compounds **4**--**8** into HeLa cells

Conclusion {#Sec7}
==========

In conclusion, we reported the series of *ortho*-carborane substituted bipolar-function derivatives, such as alkyl pyridine, alkyl phenoxide, alkyl morpholine, and alkyl piperidine, were synthesized. The target compounds coupling of the aryl-oxime with chain functional group proceeded successfully for introduction of an *ortho*-carborane moiety in the molecules, which can easily be further four-step substituted to high yield final compound. The effects of synthesized compounds on biology activity were assay in HeLa cells. Both cyclic alkyl derivatives of *ortho*-carborane and oxime containing compounds, **7** and **8**, respectively, were exhibit high boron uptake and higher cytotoxicity than BPA ([l]{.smallcaps}-boronphenylalanine). This resulted in carborane compounds with improved water solubility for the BNCT agent. The knowledge gained from modified bipolar groups could facilitate both drug selection and evaluations.

Additional file
===============

 {#Sec8}

**Additional file 1: Figure S1.** ^1^H-NMR bis(3-methoxybenzyl)carborane (**1**). **Figure S2.** ^1^H-NMR1,1′-(4-caboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one) (**2**). **Figure S3.** ^1^H-NMR (*Z,Z*′)-1,1′-(4-caboranyldimethyl)-bis(2-methoxyphenylethan-1-oxime) (**3**). **Figure S4.** ^1^H-NMR (1*Z*,1′*Z*)-1,1′-(carboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one)-*O,O*-dipyridin-2-ylmethyldioxime (**4**). **Figure S5.** ^1^H-NMR (1*Z*,1′*Z*)-1,1′-(carboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one)-*O,O*-di(2-phenoxyethyl)dioxime (**5**). **Figure S6.** ^1^H-NMR (1*Z*,1′*Z*)-1,1'-(carboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one)-*O,O*-di(3-phenoxypropyl)dioxime (**6**). **Figure S7.** ^1^H-NMR (1*Z*,1′*Z*)-1,1'-(carboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one)-*O,O*-di(2-piperidin-1-ylethyl)dioxime (**7**). **Figure S8.** ^1^H-NMR (1*Z*,1′*Z)*-1,1'-(carboranyldimethyl)-bis(2-methoxy-4,1-phenylene-ethan-1-one)-*O,O*-di(2-morpholinoethyl)dioxime (**8**).
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